Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2025-12-28 @ 2:10 AM
Study NCT ID:
NCT04630769
Status:
COMPLETED
Last Update Posted:
2023-04-03
First Post:
2020-11-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Sponsor:
Masonic Cancer Center, University of Minnesota
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2020LS001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |